APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Colorectal Cancer Molecular Diagnostics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Colorectal Cancer Molecular Diagnostics Market Outlook and Growth Opportunities 2026

Report ID 173901110422 December 2025198 pages

Choose your research edition.

Industry ResearchColorectal Cancer Molecular Diagnostics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Colorectal Cancer Molecular Diagnostics Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Colorectal Cancer Molecular Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Colorectal Cancer Molecular Diagnostics Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Colorectal Cancer Molecular Diagnostics Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Colorectal Cancer Molecular Diagnostics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Colorectal Cancer Molecular Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Colorectal Cancer Molecular Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Colorectal Cancer Molecular Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Colorectal Cancer Molecular Diagnostics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Colorectal Cancer Molecular Diagnostics market include Roche Diagnostics, Abbott, Thermo Fisher, Qiagen, Illumina, Biomerieux, Bio-Rad, Agilent and Daangene, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Colorectal Cancer Molecular Diagnostics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Colorectal Cancer Molecular Diagnostics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Colorectal Cancer Molecular Diagnostics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Colorectal Cancer Molecular Diagnostics market.

Colorectal Cancer Molecular Diagnostics Segment by Company

Roche Diagnostics

Abbott

Thermo Fisher

Qiagen

Illumina

Biomerieux

Bio-Rad

Agilent

Daangene

Amoydx

Colorectal Cancer Molecular Diagnostics Segment by Type

Polymerase Chain Reaction PCR

Molecular Hybridization

Biochip

Others

Colorectal Cancer Molecular Diagnostics Segment by Application

Hospital

Third-Party Testing Agency

Others

Colorectal Cancer Molecular Diagnostics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Colorectal Cancer Molecular Diagnostics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Colorectal Cancer Molecular Diagnostics key companies, revenue, market share, and recent developments.

3. To split the Colorectal Cancer Molecular Diagnostics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Colorectal Cancer Molecular Diagnostics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Colorectal Cancer Molecular Diagnostics significant trends, drivers, influence factors in global and regions.

6. To analyze Colorectal Cancer Molecular Diagnostics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Colorectal Cancer Molecular Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Colorectal Cancer Molecular Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Colorectal Cancer Molecular Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Colorectal Cancer Molecular Diagnostics industry.

Chapter 3: Detailed analysis of Colorectal Cancer Molecular Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Colorectal Cancer Molecular Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Colorectal Cancer Molecular Diagnostics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Colorectal Cancer Molecular Diagnostics Industry Trends Table 2. Colorectal Cancer Molecular Diagnostics Industry Drivers Table 3. Colorectal Cancer Molecular Diagnostics Industry Opportunities and Challenges Table 4. Colorectal Cancer Molecular Diagnostics Industry Restraints Table 5. Global Colorectal Cancer Molecular Diagnostics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Colorectal Cancer Molecular Diagnostics Revenue Share by Company (2021-2026) Table 7. Global Colorectal Cancer Molecular Diagnostics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Colorectal Cancer Molecular Diagnostics Key Company Manufacturing Base & Headquarters Table 9. Global Colorectal Cancer Molecular Diagnostics Company, Product Type & Application Table 10. Global Colorectal Cancer Molecular Diagnostics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Colorectal Cancer Molecular Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polymerase Chain Reaction PCR Table 15. Significant Companies of Molecular Hybridization Table 16. Significant Companies of Biochip Table 17. Significant Companies of Others Table 18. Global Colorectal Cancer Molecular Diagnostics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Colorectal Cancer Molecular Diagnostics Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Colorectal Cancer Molecular Diagnostics Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Colorectal Cancer Molecular Diagnostics Sales Value Share by Type (2021-2026) Table 22. Global Colorectal Cancer Molecular Diagnostics Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Third-Party Testing Agency Table 25. Significant Companies of Others Table 26. Global Colorectal Cancer Molecular Diagnostics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Colorectal Cancer Molecular Diagnostics Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Colorectal Cancer Molecular Diagnostics Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Colorectal Cancer Molecular Diagnostics Sales Value Share by Application (2021-2026) Table 30. Global Colorectal Cancer Molecular Diagnostics Sales Value Share by Application (2027-2032) Table 31. Global Colorectal Cancer Molecular Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Colorectal Cancer Molecular Diagnostics Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Colorectal Cancer Molecular Diagnostics Sales Value Share by Region (2021-2026) Table 34. Global Colorectal Cancer Molecular Diagnostics Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Colorectal Cancer Molecular Diagnostics Sales Value Share by Region (2027-2032) Table 36. Global Colorectal Cancer Molecular Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Colorectal Cancer Molecular Diagnostics Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Colorectal Cancer Molecular Diagnostics Sales Value Market Share by Country (2021-2026) Table 39. Global Colorectal Cancer Molecular Diagnostics Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Colorectal Cancer Molecular Diagnostics Sales Value Market Share by Country (2027-2032) Table 41. Roche Diagnostics Company Information Table 42. Roche Diagnostics Business Overview Table 43. Roche Diagnostics Colorectal Cancer Molecular Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Roche Diagnostics Colorectal Cancer Molecular Diagnostics Product Portfolio Table 45. Roche Diagnostics Recent Development Table 46. Abbott Company Information Table 47. Abbott Business Overview Table 48. Abbott Colorectal Cancer Molecular Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Abbott Colorectal Cancer Molecular Diagnostics Product Portfolio Table 50. Abbott Recent Development Table 51. Thermo Fisher Company Information Table 52. Thermo Fisher Business Overview Table 53. Thermo Fisher Colorectal Cancer Molecular Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Thermo Fisher Colorectal Cancer Molecular Diagnostics Product Portfolio Table 55. Thermo Fisher Recent Development Table 56. Qiagen Company Information Table 57. Qiagen Business Overview Table 58. Qiagen Colorectal Cancer Molecular Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Qiagen Colorectal Cancer Molecular Diagnostics Product Portfolio Table 60. Qiagen Recent Development Table 61. Illumina Company Information Table 62. Illumina Business Overview Table 63. Illumina Colorectal Cancer Molecular Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Illumina Colorectal Cancer Molecular Diagnostics Product Portfolio Table 65. Illumina Recent Development Table 66. Biomerieux Company Information Table 67. Biomerieux Business Overview Table 68. Biomerieux Colorectal Cancer Molecular Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Biomerieux Colorectal Cancer Molecular Diagnostics Product Portfolio Table 70. Biomerieux Recent Development Table 71. Bio-Rad Company Information Table 72. Bio-Rad Business Overview Table 73. Bio-Rad Colorectal Cancer Molecular Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bio-Rad Colorectal Cancer Molecular Diagnostics Product Portfolio Table 75. Bio-Rad Recent Development Table 76. Agilent Company Information Table 77. Agilent Business Overview Table 78. Agilent Colorectal Cancer Molecular Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Agilent Colorectal Cancer Molecular Diagnostics Product Portfolio Table 80. Agilent Recent Development Table 81. Daangene Company Information Table 82. Daangene Business Overview Table 83. Daangene Colorectal Cancer Molecular Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Daangene Colorectal Cancer Molecular Diagnostics Product Portfolio Table 85. Daangene Recent Development Table 86. Amoydx Company Information Table 87. Amoydx Business Overview Table 88. Amoydx Colorectal Cancer Molecular Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Amoydx Colorectal Cancer Molecular Diagnostics Product Portfolio Table 90. Amoydx Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Colorectal Cancer Molecular Diagnostics Product Image Figure 2. Global Colorectal Cancer Molecular Diagnostics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Colorectal Cancer Molecular Diagnostics Market Size (2021-2032) & (US$ Million) Figure 4. Global Colorectal Cancer Molecular Diagnostics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polymerase Chain Reaction PCR Image Figure 8. Molecular Hybridization Image Figure 9. Biochip Image Figure 10. Others Image Figure 11. Global Colorectal Cancer Molecular Diagnostics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Colorectal Cancer Molecular Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Colorectal Cancer Molecular Diagnostics Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Third-Party Testing Agency Image Figure 16. Others Image Figure 17. Global Colorectal Cancer Molecular Diagnostics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Colorectal Cancer Molecular Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Colorectal Cancer Molecular Diagnostics Sales Value Share by Application (2021-2032) Figure 20. Global Colorectal Cancer Molecular Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Colorectal Cancer Molecular Diagnostics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Colorectal Cancer Molecular Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 23. North America Colorectal Cancer Molecular Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Colorectal Cancer Molecular Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Colorectal Cancer Molecular Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Colorectal Cancer Molecular Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Colorectal Cancer Molecular Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Colorectal Cancer Molecular Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 29. South America Colorectal Cancer Molecular Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Colorectal Cancer Molecular Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Colorectal Cancer Molecular Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polymerase Chain Reaction PCR
  • Molecular Hybridization
  • Biochip
  • Others
Applications
  • Hospital
  • Third-Party Testing Agency
  • Others
Companies covered
  • Roche Diagnostics
  • Abbott
  • Thermo Fisher
  • Qiagen
  • Illumina
  • Biomerieux
  • Bio-Rad
  • Agilent
  • Daangene
  • Amoydx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Colorectal Cancer Molecular Diagnostics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Colorectal Cancer Molecular Diagnostics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Colorectal Cancer Molecular Diagnostics Market Dynamics
  1. 2.1 Colorectal Cancer Molecular Diagnostics Industry Trends
  2. 2.2 Colorectal Cancer Molecular Diagnostics Industry Drivers
  3. 2.3 Colorectal Cancer Molecular Diagnostics Industry Opportunities and Challenges
  4. 2.4 Colorectal Cancer Molecular Diagnostics Industry Restraints
3 Colorectal Cancer Molecular Diagnostics Market by Company
  1. 3.1 Global Colorectal Cancer Molecular Diagnostics Company Revenue Ranking in 2025
  2. 3.2 Global Colorectal Cancer Molecular Diagnostics Revenue by Company (2021-2026)
  3. 3.3 Global Colorectal Cancer Molecular Diagnostics Company Ranking (2024-2026)
  4. 3.4 Global Colorectal Cancer Molecular Diagnostics Company Manufacturing Base and Headquarters
  5. 3.5 Global Colorectal Cancer Molecular Diagnostics Company Product Type and Application
  6. 3.6 Global Colorectal Cancer Molecular Diagnostics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Colorectal Cancer Molecular Diagnostics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Colorectal Cancer Molecular Diagnostics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Colorectal Cancer Molecular Diagnostics Market by Type
  1. 4.1 Colorectal Cancer Molecular Diagnostics Type Introduction
  2. 4.1.1 Polymerase Chain Reaction PCR
  3. 4.1.2 Molecular Hybridization
  4. 4.1.3 Biochip
  5. 4.1.4 Others
  6. 4.2 Global Colorectal Cancer Molecular Diagnostics Sales Value by Type
  7. 4.2.1 Global Colorectal Cancer Molecular Diagnostics Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Colorectal Cancer Molecular Diagnostics Sales Value by Type (2021-2032)
  9. 4.2.3 Global Colorectal Cancer Molecular Diagnostics Sales Value Share by Type (2021-2032)
5 Colorectal Cancer Molecular Diagnostics Market by Application
  1. 5.1 Colorectal Cancer Molecular Diagnostics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Third-Party Testing Agency
  4. 5.1.3 Others
  5. 5.2 Global Colorectal Cancer Molecular Diagnostics Sales Value by Application
  6. 5.2.1 Global Colorectal Cancer Molecular Diagnostics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Colorectal Cancer Molecular Diagnostics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Colorectal Cancer Molecular Diagnostics Sales Value Share by Application (2021-2032)
6 Colorectal Cancer Molecular Diagnostics Regional Value Analysis
  1. 6.1 Global Colorectal Cancer Molecular Diagnostics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Colorectal Cancer Molecular Diagnostics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Colorectal Cancer Molecular Diagnostics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Colorectal Cancer Molecular Diagnostics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Colorectal Cancer Molecular Diagnostics Sales Value (2021-2032)
  7. 6.3.2 North America Colorectal Cancer Molecular Diagnostics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Colorectal Cancer Molecular Diagnostics Sales Value (2021-2032)
  10. 6.4.2 Europe Colorectal Cancer Molecular Diagnostics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Colorectal Cancer Molecular Diagnostics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Colorectal Cancer Molecular Diagnostics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Colorectal Cancer Molecular Diagnostics Sales Value (2021-2032)
  16. 6.6.2 South America Colorectal Cancer Molecular Diagnostics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Colorectal Cancer Molecular Diagnostics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Colorectal Cancer Molecular Diagnostics Sales Value Share by Country, 2025 VS 2032
7 Colorectal Cancer Molecular Diagnostics Country-level Value Analysis
  1. 7.1 Global Colorectal Cancer Molecular Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Colorectal Cancer Molecular Diagnostics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Colorectal Cancer Molecular Diagnostics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Colorectal Cancer Molecular Diagnostics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Colorectal Cancer Molecular Diagnostics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Colorectal Cancer Molecular Diagnostics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Colorectal Cancer Molecular Diagnostics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche Diagnostics
  2. 8.1.1 Roche Diagnostics Company Information
  3. 8.1.2 Roche Diagnostics Business Overview
  4. 8.1.3 Roche Diagnostics Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche Diagnostics Colorectal Cancer Molecular Diagnostics Product Portfolio
  6. 8.1.5 Roche Diagnostics Recent Developments
  7. 8.2 Abbott
  8. 8.2.1 Abbott Company Information
  9. 8.2.2 Abbott Business Overview
  10. 8.2.3 Abbott Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbott Colorectal Cancer Molecular Diagnostics Product Portfolio
  12. 8.2.5 Abbott Recent Developments
  13. 8.3 Thermo Fisher
  14. 8.3.1 Thermo Fisher Company Information
  15. 8.3.2 Thermo Fisher Business Overview
  16. 8.3.3 Thermo Fisher Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Thermo Fisher Colorectal Cancer Molecular Diagnostics Product Portfolio
  18. 8.3.5 Thermo Fisher Recent Developments
  19. 8.4 Qiagen
  20. 8.4.1 Qiagen Company Information
  21. 8.4.2 Qiagen Business Overview
  22. 8.4.3 Qiagen Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Qiagen Colorectal Cancer Molecular Diagnostics Product Portfolio
  24. 8.4.5 Qiagen Recent Developments
  25. 8.5 Illumina
  26. 8.5.1 Illumina Company Information
  27. 8.5.2 Illumina Business Overview
  28. 8.5.3 Illumina Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Illumina Colorectal Cancer Molecular Diagnostics Product Portfolio
  30. 8.5.5 Illumina Recent Developments
  31. 8.6 Biomerieux
  32. 8.6.1 Biomerieux Company Information
  33. 8.6.2 Biomerieux Business Overview
  34. 8.6.3 Biomerieux Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Biomerieux Colorectal Cancer Molecular Diagnostics Product Portfolio
  36. 8.6.5 Biomerieux Recent Developments
  37. 8.7 Bio-Rad
  38. 8.7.1 Bio-Rad Company Information
  39. 8.7.2 Bio-Rad Business Overview
  40. 8.7.3 Bio-Rad Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bio-Rad Colorectal Cancer Molecular Diagnostics Product Portfolio
  42. 8.7.5 Bio-Rad Recent Developments
  43. 8.8 Agilent
  44. 8.8.1 Agilent Company Information
  45. 8.8.2 Agilent Business Overview
  46. 8.8.3 Agilent Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Agilent Colorectal Cancer Molecular Diagnostics Product Portfolio
  48. 8.8.5 Agilent Recent Developments
  49. 8.9 Daangene
  50. 8.9.1 Daangene Company Information
  51. 8.9.2 Daangene Business Overview
  52. 8.9.3 Daangene Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Daangene Colorectal Cancer Molecular Diagnostics Product Portfolio
  54. 8.9.5 Daangene Recent Developments
  55. 8.10 Amoydx
  56. 8.10.1 Amoydx Company Information
  57. 8.10.2 Amoydx Business Overview
  58. 8.10.3 Amoydx Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Amoydx Colorectal Cancer Molecular Diagnostics Product Portfolio
  60. 8.10.5 Amoydx Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst